Internal sdAb Discovery Program
Undisclosed
DiscoveryActive
Key Facts
About NanoTag Biotechnologies
NanoTag Biotechnologies is a private, revenue-generating platform and services company specializing in the discovery, engineering, and production of single-domain antibodies (nanobodies). Its core business model combines a portfolio of validated research reagents (e.g., FluoTags®, Smart Secondaries®, Selector resins) with custom contract research services for sdAb discovery and protein production. The company has secured a significant strategic partnership with BioNTech to evaluate its proprietary ALFA labeling technology across therapeutic areas, indicating a strategic pivot towards therapeutic and diagnostic applications alongside its strong R&D tools business.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| ASPEN Study Program | Insmed | Phase 3 |
| ARISE Study Program | Insmed | Phase 3 |
| MGL-2086 | Madrigal Pharmaceuticals | Phase 1 |
| Innovative Proprietary/Licensed Products | Laboratorios Farmaceuticos Rovi | Various |
| Undisclosed Partnered Program | Septerna | Discovery |
| Undisclosed Cell Therapy | Immix Biopharma | Pre-clinical |
| HTL0039732 | Nxera Pharma | Preclinical |
| LYT-310 | PureTech Health | Preclinical |
| Bispecific (Undisclosed) | MacroGenics | Preclinical |
| Sec61 Portfolio Assets | Kezar Life Sciences | Preclinical |
| WTX-518 | Werewolf Therapeutics | Preclinical |
| WTX-712 | Werewolf Therapeutics | Preclinical |